Home/Filings/4/0001209191-15-034141

4//SEC Filing

Adamas Pharmaceuticals Inc 4

Accession 0001209191-15-034141

CIK 0001328143operating

View on SEC.gov Company Profile

Filed

Apr 13, 8:00 PM ET

Accepted

Apr 14, 8:00 PM ET

Size

22.1 KB

Accession

0001209191-15-034141

Insider Transaction Report

Form 4

Period: 2015-04-10

Adamas Pharmaceuticals IncADMS

SCHOENDORF NANCY J

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661

Ninth MDV Partners, L.L.C.

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686

FEIBER JONATHAN D

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043

Seventh MDV Partners, L.L.C.

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146

MDV ENF VII (A), L.P.

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661

MDV IX LP

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661

MDV VII LP

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661

MDV ENF VII (B), L.P.

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661
Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043

MDV VII Leaders' Fund, L.P.

10% Owner

Transactions

Sale
Common Stock
2015-04-10$18.56/sh−37,078$688,056→ 462,527 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF)

Holdings

Common Stock
(indirect: MDV ENF VII (B), L.P.)
3,146
Common Stock
(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
3,772,686
Common Stock
(indirect: MDV VII, L.P.)
265,150
Common Stock
(indirect: MDV ENF VII (A), L.P.)
6,043
Common Stock
(indirect: MDV VII Leaders' Fund, L.P.)
25,661

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by MDV IX on December 15, 2014.
[F2]Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $18.00 and $18.0900 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
[F3]Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
[F4]Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001328143

Filing Metadata

Form type: 4
Filed: Apr 13, 8:00 PM ET
Accepted: Apr 14, 8:00 PM ET
Size: 22.1 KB

View on SEC.gov